IVD China last week: Mindray, Sansure, YHLO, Autobio and DeepSeek, Andon Health, MGI

Mindray’s Second Headquarters to Fully Launch

Mindray’s Second Headquarters, located in Wuhan’s Optics Valley Bio-City, is set to be fully operational. As one of the world’s leading and China’s largest medical device R&D and manufacturing companies, Mindray’s product portfolio covers three major areas: patient monitoring and life support, in vitro diagnostics, and medical imaging, with a sales network spanning over 190 countries and regions worldwide.

The Wuhan facility, with a total investment of 4.5 billion CNY and a construction area of approximately 530,000 square meters, consists of two major sub-projects: the Wuhan Research Institute and the Manufacturing Base. The Wuhan Research Institute is positioned as a super-scale R&D center, focusing on biomedical engineering research, including biological raw materials and reagent development, surgical equipment innovation, and health technology research. The institute has completed all 290,000 cubic meters of foundational construction and is currently undergoing interior decoration in designated areas. The first batch of R&D personnel has already moved in, and the entire facility is expected to be fully operational in the first half of 2025.

Sansure, YHLO, and Autobio Integrate DeepSeek

On February 12, Sansure Biotech officially integrated its intelligent sequencing system with DeepSeek, applying it comprehensively to pathogen sequencing solutions and accelerating the implementation of AI-driven medical technology. With both respiratory and sequencing systems integrated into DeepSeek, Sansure demonstrates its speed and commitment to fully embracing AI.

On February 11, YHLO launched two major computing power centers dedicated to supporting its R&D systems, internal operations, and data systems. Leveraging DeepSeek technology as the core driving force, YHLO is not only transforming its products through intelligent upgrades but also deeply reshaping its operational efficiency. In software development, DeepSeek has empowered YHLO to efficiently convert business needs into high-quality code, significantly boosting coding speed. Additionally, its built-in AI code review system detects potential vulnerabilities in real-time, accelerating the review process and ensuring both security and quality.

On February 11, Autobio successfully completed the localized deployment of the DeepSeek-R1 model, enhancing core functions of the "Autobio AI Laboratory Clinical Decision Support System." By integrating DeepSeek with RAG technology, Autobio has upgraded intelligent query, report interpretation, and factor analysis functionalities, marking another significant breakthrough in its AI technology applications.

Andon Health Fully Acquires iHealth

On February 12, Andon Health announced that its wholly-owned subsidiary, Andon Hong Kong, would purchase a 20% stake in iHealth Inc. from Xiaomi Investment for $45.91 million. Following this transaction, Andon Health's ownership of iHealth will increase from 80% to 100%, completing its full acquisition.

Andon Health has actively expanded its presence in the IVD field. Through iHealth, the company has built a differentiated product portfolio, including COVID-19 test kits, blood glucose monitoring devices, and smart hardware. In terms of business model innovation, its "O+O" model for diabetes management integrates online data management with offline medical services, capturing the chronic disease management market and forming a closed-loop system with its IVD products. Furthermore, iHealth's brand recognition and channel resources in the US market provide a solid foundation for Andon Health's overseas IVD market expansion.

OC Medicina de Precisão Partners with MGI

Recently, OC Medicina de Precisão, the precision medicine laboratory under Latin America’s largest cancer treatment group, Oncoclínicas & Co, announced a partnership with MGI. This collaboration will leverage OC Medicina de Precisão’s oncology service management system and MGI’s advanced technology and equipment to drive innovation in Brazil’s precision medicine sector, offering more efficient and personalized diagnostic and treatment solutions for patients.

Founded in 2010, Oncoclínicas & Co is a pioneer in oncology service management in Brazil and is now one of the largest oncology, hematology, and radiotherapy centers in Latin America. This partnership further demonstrates MGI’s commitment to improving the accessibility and quality of genetic sequencing technology and accelerating the development of personalized cancer treatment in Brazil through collaborations with local laboratories and diagnostic institutions.